NBRV - Nabriva Therapeutics: 2 Novel Antibiotics 2 Sets Of Problems
Nabriva Therapeutics (NBRV) has two separate drugs in regulatory stages, with lefamulin (IV/oral) targeting community-acquired bacterial pneumonia ((CABP)) and Contepo ((IV)) targeting cUTI or complicated urinary tract infection. Contepo has a PDUFA on April 30, 2019, and lefamulin on August 19, 2019. Trading as it is at almost 60% discount to its 52-week high, the catalysts do offer some opportunity of short-term gains. However, the company has a number of longer term problems in its value thesis that make it a doubtful long-term investment.
Cost-benefit issues of lefamulin
Lefamulin is pleuromutilin class of